Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

Published:2009-08 Issue:3 Volume:30 Page:210-226
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

LICHTENSTEIN G. R.,DIAMOND R. H.,WAGNER C. L.,FASANMADE A. A.,OLSON A. D.,MARANO C. W.,JOHANNS J.,LANG Y.,SANDBORN W. J.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2009.04027.x/fullpdf

Reference32 articles.

1. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease;Targan;N Engl J Med,1997

2. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial;Hanauer;Lancet,2002

3. Infliximab for the treatment of fistulas in patients with Crohn’s disease;Present;N Engl J Med,1999

4. Infliximab maintenance therapy for fistulizing Crohn’s disease;Sands;N Engl J Med,2004

5. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005

Cited by 181 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complementary Therapeutic Effect of Fecal Microbiota Transplantation in Ulcerative Colitis after the Response to Anti-Tumor Necrosis Factor Alpha Agent Was Lost: A Case Report;Biomedicines;2024-04-03

2. Biological treatment interruption in inflammatory bowel disease: Motivation and predictive factors;Gastroenterología y Hepatología (English Edition);2023-11

3. Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease;Clinical and Translational Gastroenterology;2023-07-14

4. Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study;Journal of Pediatric Gastroenterology & Nutrition;2023-06-15

5. Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial;Clinical Drug Investigation;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3